ticagrelor administered as standard tablet or orodispersible formulation

Conditions: ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation MI

Summary: randomized clinical study evaluating superiority in platelet inhibition after administration of ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for st elevation myocardial infarction or very high-risk non-st elevation myocardial infarction.

primary percutaneous coronary intervention (ppci) is the preferred reperfusion strategy for patients with acute st-segment elevation myocardial infarction (stemi). additional antithrombotic therapy prior or during intervention plays an important role in the short- and long-term outcomes after ppci. oral antiplatelet therapy including a platelet p2y12 receptor inhibitors is a cornerstone of antithrombotic treatment in patients with acute coronary syndromes. prasugrel and ticagrelor have been shown to be superior to clopidogrel in patients with stemi in reduction of ischemic complication without any increase in the bleeding risk and with a significant reduction in the stent thrombosis rate. nevertheless, in stemi patients, pharmacodynamic studies showed prasugrel and ticagrelor oral loading dose (ld) provided a suboptimal platelet inhibition in the first hours after ld, and at least 4 hours are required to achieve and effective platelet aggregation inhibition in the majority of patients, in part due to slowed gut motility caused by morphine use. orodispersible tablet (odt) is a different tablet formulation that disperses upon contact with the moist mucosal surfaces of the oral cavity and quickly release its components before swallowing; thus local drug dissolution and absorption as well as onset of clinical effect can be obtained conveniently easily and quickly by bypassing gastrointestinal tract. recently, ticagrelor 90 mg odt has become available and bioequivalence studies on healthy volunteers documented its effectiveness with consequent approval by european medicine agency of this formulation which is currently available on the market. thus, the aim of the present study is to evaluate the superiority in platelet inhibition with 180 mg ticagrelor loading dose (ld) administered as odts as compared with standard formulation, among patients with stemi or very high-risk nstemi undergoing immediate pci. primary objective consists in evaluating platelet reactivity 1 hour after ticagrelor loading dose by verifynow test.

Eligibility criteria:
inclusion criteria: 1. patients presenting within 12 hours from the onset of symptoms with stemi or very high-risk nstemi referred for immediate (\< 2 hours) angiography. very high-risk nstemi patients include patients with haemodynamic instability or cardiogenic shock, heart failure, life-threatening arrhythmias or resuscitated cardiac arrest, intermittent st-segment elevation, or ongoing chest pain. 2. informed, written consent 3. male or female patients, aged ≥ 18 years old exclusion criteria: 1. age \< 18 years 2. active bleeding; bleeding diathesis; coagulopathy 3. history of gastrointestinal or genitourinary bleeding \<2 months 4. major surgery in the last 6 weeks 5. history of intracranial bleeding or structural abnormalities 6. suspected aortic dissection 7. administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux. 8. concomitant oral or iv therapy with strong cyp3a inhibitors or strong cyp3a inducers, cyp3a with narrow therapeutic window 9. known relevant hematological deviations: hb \<10 g/dl, thromb. \<100x10\^9/l 10. use of warfarin or new oral anticoagulant derivatives within the last 7 days 11. known severe liver disease, severe renal failure 12. allergy or hypersensitivity to ticagrelor or any of the excipients. 13. pregnancy or lactation